RT Journal Article
SR Electronic
T1 SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates Against Symptomatic Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.24.21266812
DO 10.1101/2021.11.24.21266812
A1 Schuh, Amy J.
A1 Satheshkumar, Panayampalli S.
A1 Dietz, Stephanie
A1 Bull-Otterson, Lara
A1 Charles, Myrna
A1 Edens, Chris
A1 Jones, Jefferson M.
A1 Bajema, Kristina L.
A1 Clarke, Kristie E.N.
A1 McDonald, L. Clifford
A1 Patel, Sadhna
A1 Cuffe, Kendra
A1 Thornburg, Natalie J.
A1 Schiffer, Jarad
A1 Chun, Kelly
A1 Bastidas, Monique
A1 Fernando, Manory
A1 Petropoulos, Christos J.
A1 Wrin, Terri
A1 Cai, Suqin
A1 Adcock, Dot
A1 Sesok-Pizzini, Deborah
A1 Letovsky, Stanley
A1 Fry, Alicia M.
A1 Hall, Aron J.
A1 Gundlapalli, Adi V.
YR 2021
UL http://medrxiv.org/content/early/2021/11/26/2021.11.24.21266812.abstract
AB Previous vaccine efficacy (VE) studies have estimated neutralizing and binding antibody concentrations that correlate with protection from symptomatic infection; how these estimates compare to those generated in response to SARS-CoV-2 infection is unclear. Here, we assessed quantitative neutralizing and binding antibody concentrations using standardized SARS-CoV-2 assays on 3,067 serum specimens collected during July 27, 2020-August 27, 2020 from COVID-19 unvaccinated persons with detectable anti-SARS-CoV-2 antibodies using qualitative antibody assays. Quantitative neutralizing and binding antibody concentrations were strongly positively correlated (r=0.76, p<0.0001) and were noted to be several fold lower in the unvaccinated study population as compared to published data on concentrations noted 28 days post-vaccination. In this convenience sample, ∼88% of neutralizing and ∼63-86% of binding antibody concentrations met or exceeded concentrations associated with 70% COVID-19 VE against symptomatic infection from published VE studies; ∼30% of neutralizing and 1-14% of binding antibody concentrations met or exceeded concentrations associated with 90% COVID-19 VE. These data support observations of infection-induced immunity and current recommendations for vaccination post infection to maximize protection against symptomatic COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the United States Centers for Disease Control and Prevention, Atlanta, Georgia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy (45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.). Informed consent was waived, as all data were deidentified.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.